EUVIMEDOpdag EUVIMED
Randomisierte kontrollierte StudieMultizentrische StudieKlinische Studie (Phase II)Klinische Studie (Phase III)Open access · CC BY-NC 4.0

Adjunctive brexpiprazole 1 mg and 2 mg daily for Japanese patients with major depressive disorder following inadequate response to antidepressants: a phase 2/3, randomized, double‐blind ( BLESS ) study

Masaki Kato iD, Masako Shiosakai, Kazuo Kuwahara, Katsuhiro Iba, Yuki Shimada, Mizuki Saito, Yuki Isogai iD, Daisuke Sekine, Kazuo Aoki, Nobuyuki Koga, Teruhiko Higuchi

Psychiatry and Clinical Neurosciences · 2024-02 · 78 (2) · 113-122

DOI: 10.1111/pcn.13615 ↗

At a glance

Randomisierte kontrollierte Studie in Psychiatry and Clinical Neurosciences, 2023-12. Written by Masaki Kato and 10 co-authors. Institution: Department of Neuropsychiatry, Kansai Medical University, Osaka, Japan. Major MEDLINE topics: Major Depressive Disorder, Thiophenes, Quinolones. Cited 9 times so far (Crossref); 38 references. The full text is freely available (open access, CC BY-NC 4.0). Funded by: Otsuka Pharmaceutical Co., Ltd., Otsuka Pharmaceutical.

AbstractSubjectsBibliografiske oplysningerCiteRelated studies

Abstract (original language)

Aims

Inadequate antidepressant response interrupts effective treatment of major depressive disorder (MDD). The BLESS study evaluates the dosage, efficacy, and safety of brexpiprazole adjunctive therapy in Japanese patients with inadequate antidepressant therapy (ADT) response.

Methods

This placebo‐controlled, randomized, multicenter, parallel‐group phase 2/3 study randomized Japanese MDD patients (Hamilton Rating Scale for Depression 17‐item total score ≥ 14; historical inadequate response to 1–3 ADTs) with inadequate response to 8‐week single‐blind, prospective SSRI/SNRI treatment to 6‐week adjunctive treatment with brexpiprazole 1 mg, 2 mg, or placebo. The primary endpoint was change in Montgomery‐Åsberg Depression Rating Scale (MADRS) total score from baseline. Secondary endpoints included MADRS response, remission rate, and Clinical Global Impression‐Improvement score. Safety was comprehensively evaluated, especially regarding antipsychotic adverse events (AEs).

Results

Of 1194 screened patients, 740 were randomized and 736 (1 mg, n = 248; 2 mg, n = 245; placebo, n = 243) had ≥1 baseline/post‐baseline MADRS total score. The LSM (SE) change from baseline in MADRS total score at Week 6 by MMRM analysis was −8.5 (0.47) with brexpiprazole 1 mg, −8.2 (0.47) with brexpiprazole 2 mg, and −6.7 (0.47) with placebo (placebo‐adjusted LSM difference [95% CI]: 1 mg, −1.7 [−3.0, −0.4]; P = 0.0089; 2 mg, −1.4 [−2.7, −0.1]; P = 0.0312). Secondary efficacy results supported the primary endpoint. Brexpiprazole was generally well tolerated.

Conclusion

Brexpiprazole 1 mg daily was an appropriate starting dose and both 1 mg and 2 mg daily were effective and well tolerated as adjunctive therapy for Japanese MDD patients not adequately responsive to ADT.

Subjects

MeSH terms (MEDLINE)

Major Depressive DisorderThiophenesQuinolonesHumansProspective StudiesJapanSingle-Blind MethodDrug Therapy, CombinationAntidepressive AgentsTreatment OutcomeDouble-Blind Method

Author keywords

Japaneseadjunctive therapyantipsychoticbrexpiprazolemajor depressive disorder

Substances

brexpiprazoleAntidepressive AgentsThiophenesQuinolones

Authors and institutions

  • Department of Neuropsychiatry, Kansai Medical University, Osaka, Japan.
  • Clinical Development, Headquarters of Clinical Development Otsuka Pharmaceutical Co. Ltd., Tokyo, Japan.
  • Clinical Development, Headquarters of Clinical Development Otsuka Pharmaceutical Co. Ltd., Osaka, Japan.
  • Medical Affairs, Otsuka Pharmaceutical Co., Ltd., Tokyo, Japan.
  • Medical Affairs, Otsuka Pharmaceutical Co., Ltd., Tokushima, Japan.
  • Japan Depression Center, Tokyo, Japan.

ORCID profiles: Masaki Kato, Yuki Isogai

Funding

  • Otsuka Pharmaceutical Co., Ltd.
  • Otsuka Pharmaceutical

Cite

APA

Kato, M., Shiosakai, M., Kuwahara, K., Iba, K., Shimada, Y., Saito, M., Isogai, Y., Sekine, D., Aoki, K., Koga, N., & Higuchi, T. (2024). Adjunctive brexpiprazole 1 mg and 2 mg daily for Japanese patients with major depressive disorder following inadequate response to antidepressants: a phase 2/3, randomized, double‐blind ( BLESS ) study. Psychiatry and Clinical Neurosciences, 78(2), 113-122. https://doi.org/10.1111/pcn.13615

Vancouver

Kato M, Shiosakai M, Kuwahara K, Iba K, Shimada Y, Saito M, et al. Adjunctive brexpiprazole 1 mg and 2 mg daily for Japanese patients with major depressive disorder following inadequate response to antidepressants: a phase 2/3, randomized, double‐blind ( BLESS ) study. Psychiatry and Clinical Neurosciences. 2024;78(2):113-122. doi:10.1111/pcn.13615

BibTeX
@article{Kato2024,
  author = {Kato, Masaki and Shiosakai, Masako and Kuwahara, Kazuo and Iba, Katsuhiro and Shimada, Yuki and Saito, Mizuki and Isogai, Yuki and Sekine, Daisuke and Aoki, Kazuo and Koga, Nobuyuki and Higuchi, Teruhiko},
  title = {Adjunctive brexpiprazole 1 mg and 2 mg daily for Japanese patients with major depressive disorder following inadequate response to antidepressants: a phase 2/3, randomized, double‐blind ( BLESS ) study},
  journal = {Psychiatry and Clinical Neurosciences},
  year = {2024},
  volume = {78},
  number = {2},
  pages = {113--122},
  doi = {10.1111/pcn.13615}
}
Start for free →